Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling-Reference-Cited by-同舟云学术

Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling

Published:2023-11-01 Issue:5 Volume:325 Page:H1210-H1222
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Bakbak Ehab¹²³^ORCID,Verma Subodh¹²³⁴^ORCID,Krishnaraj Aishwarya¹²³^ORCID,Quan Adrian²³,Wang Chao-Hung⁵⁶^ORCID,Pan Yi²³,Puar Pankaj¹²³⁷^ORCID,Mason Tamique²³,Verma Raj²⁸,Terenzi Daniella C.⁹,Rotstein Ori D.³⁴¹⁰,Yan Andrew T.³¹¹¹²,Connelly Kim A.³¹¹¹²¹³^ORCID,Teoh Hwee²³¹⁴^ORCID,Mazer C. David¹³¹³¹⁵¹⁶^ORCID,Hess David A.¹³¹⁷¹⁸^ORCID

Affiliation:

1. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

2. Division of Cardiac Surgery, St. Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada

3. Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, Ontario, Canada

4. Department of Surgery, University of Toronto, Toronto, Ontario, Canada

5. Division of Cardiology, Department of Internal Medicine, Heart Failure Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

6. School of Medicine, Chang Gung University, Taoyuan, Taiwan

7. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

8. School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

9. Faculty of Medicine, University College Dublin, Dublin, Ireland

10. Division of General Surgery, St. Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada

11. Division of Cardiology, St Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada

12. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

13. Department of Physiology, University of Toronto, Toronto, Ontario, Canada

14. Division of Endocrinology and Metabolism, St. Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada

15. Department of Anesthesia, St. Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada

16. Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada

17. Department of Physiology and Pharmacology, Western University, London, Ontario, Canada

18. Molecular Medicine Research Laboratories, Robarts Research Institute, London, Ontario, Canada

Abstract

Using an aldehyde dehydrogenase (ALDH) activity-based flow cytometry assay, we found that empagliflozin treatment for 6 mo was associated with parallel increases in circulating vascular regenerative ALDHhi-CD34/CD133-coexpressing progenitors and decreased proinflammatory ALDHhi-CD14/CD86-coexpressing monocyte precursors in individuals without diabetes but with cardiovascular risk factors. The rejuvenation of the vascular regenerative cell reservoir may represent a mechanism via which sodium glucose-cotransporter 2 (SGLT2) inhibitors limit maladaptive repair and delay the development and progression of cardiovascular diseases.

Funder

Chang Guing Memorial Hospital

Boehringer Ingelheim

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00141.2023

Reference72 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

2. One size fits all: The story of SGLT2 inhibitors in heart failure